Endocrinology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Endocrinology Search

Endocrinology

Endocrinology

Home News Diseases Conferences Special Reports Multimedia

Dietary flaxseed may help prevent breast cancer in postmenopausal women

Yesterday

Dietary flaxseed and tamoxifen both affect normal breast tissue in vivo, a study has shown, adding that a relatively modest change in the diet can lead to significant effects on the breast microenvironment.

High-dose teriparatide + denosumab improves BMD in postmenopausal osteoporosis

Roshini Claire Anthony, 2 days ago

Combining high-dose teriparatide with denosumab may improve areal bone mineral density (aBMD) in postmenopausal women with osteoporosis, according to results of the phase IV DATA-HD* study.

UTI risk not raised with SGLT-2is in real-world study

Pearl Toh, 3 days ago

The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Novel clinical risk score identifies T2D patients at greatest risk of heart failure

Roshini Claire Anthony, 4 days ago

A newly developed clinical risk score can identify patients with type 2 diabetes (T2D) at greatest risk for hospitalization for heart failure (HHF) who would derive the most benefit from treatment with dapagliflozin, according to a study presented at ESC 2019.

A Paradigm Shift in the Assessment and Management of Atherosclerotic Cardiovascular Disease Risk

11 Sep 2019

At the recent 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress(MAC) held in Hilton Kuala Lumpur, Dr Wong Ming, a consultant endocrinologist from Sunway Medical Centre, spoke on the role of non–high-density lipoprotein cholesterol (non–HDL-c) as an emerging marker and treatment target for cardiovascular (CV) disease. Additionally, she also highlighted the role of fenofibrate in delaying and preventing diabetic retinopathy (DR).

DIABESITY AND THE ROLE OF DIABETIC-SPECIFIC FORMULA IN IMPROVING DIABETES AND OBESITY OUTCOMES

02 May 2019

At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.

Strategies for the long-term practical management of T2DM

24 Apr 2019

At the recent 12th IDF-WPR Congress and 10th AASD Scientific Meeting held at Kuala Lumpur Convention Centre, the importance of glycaemic control and the practical management of type 2 diabetes mellitus (T2DM) were highlighted by two international speakers, Dr Sanjay Kalra from India and Professor Jean Claude Mbanya from Cameroon.

Fenofibrate linked with reduced CV risk and DR progression, but how?

28 Nov 2018

At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.

Improving glycaemic outcomes and providing cardiovascular protection in patients with T2DM

21 Nov 2018

At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.

Optimizing CV outcomes with evolocumab

Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

Novel clinical risk score identifies T2D patients at greatest risk of heart failure

Roshini Claire Anthony, 16 Sep 2019

Ticagrelor-based DAPT may benefit select stable CAD patients with T2D

Audrey Abella, 11 Sep 2019

The addition of ticagrelor to aspirin significantly reduced ischaemic events but led to an upsurge in major bleeding events relative to aspirin alone in individuals with stable coronary artery disease (CAD) and type 2 diabetes (T2D) without prior myocardial infarction (MI) or stroke. However, there was a favourable net clinical benefit in a subgroup with prior percutaneous coronary intervention (PCI), according to the results of the THEMIS* and THEMIS-PCI trials presented at the ESC Congress 2019.

Dapagliflozin cuts risk of CV death/HHF even in patients with more severe CKD

Pearl Toh, 06 Sep 2019

Dapagliflozin consistently reduced the composite outcome of cardiovascular (CV) death and HHF* in patients with type 2 diabetes (T2D) regardless of kidney function, with the greatest benefit seen in those with both reduced eGFR and albuminuria, new insights from the DECLARE-TIMI 58 trial revealed.